Evaluation of eltrombopag in patients with aplastic anemia in real-world experience

BACKGROUND: Although eltrombopag has recently been approved for treating AA, the effects of its clinical use remain unknown. METHODS: We retrospectively analyzed 11 patients with AA, who had been treated with eltrombopag from August 2017 to May 2018. RESULTS: Overall response rate was 55%. There was...

Descripción completa

Detalles Bibliográficos
Autores principales: Konishi, Akiko, Nakaya, Aya, Fujita, Shinya, Satake, Atsushi, Nakanishi, Takahisa, Azuma, Yoshiko, Tsubokura, Yukie, Saito, Ryo, Hotta, Masaaki, Yoshimura, Hideaki, Ishii, Kazuyoshi, Ito, Tomoki, Nomura, Shosaku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416522/
https://www.ncbi.nlm.nih.gov/pubmed/30911464
http://dx.doi.org/10.1016/j.lrr.2019.03.002
_version_ 1783403370805985280
author Konishi, Akiko
Nakaya, Aya
Fujita, Shinya
Satake, Atsushi
Nakanishi, Takahisa
Azuma, Yoshiko
Tsubokura, Yukie
Saito, Ryo
Hotta, Masaaki
Yoshimura, Hideaki
Ishii, Kazuyoshi
Ito, Tomoki
Nomura, Shosaku
author_facet Konishi, Akiko
Nakaya, Aya
Fujita, Shinya
Satake, Atsushi
Nakanishi, Takahisa
Azuma, Yoshiko
Tsubokura, Yukie
Saito, Ryo
Hotta, Masaaki
Yoshimura, Hideaki
Ishii, Kazuyoshi
Ito, Tomoki
Nomura, Shosaku
author_sort Konishi, Akiko
collection PubMed
description BACKGROUND: Although eltrombopag has recently been approved for treating AA, the effects of its clinical use remain unknown. METHODS: We retrospectively analyzed 11 patients with AA, who had been treated with eltrombopag from August 2017 to May 2018. RESULTS: Overall response rate was 55%. There was tri-lineage recovery in four patients and platelet recovery in two. The reactive time was within 8 weeks after treatment initiation. Stage at the initial assessment, the neutrophil-to-lymphocyte ratio and platelet counts were significantly different between the responders and non-responders. CONCLUSION: Eltrombopag is a promising agent for treating patients with any degree of AA.
format Online
Article
Text
id pubmed-6416522
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-64165222019-03-25 Evaluation of eltrombopag in patients with aplastic anemia in real-world experience Konishi, Akiko Nakaya, Aya Fujita, Shinya Satake, Atsushi Nakanishi, Takahisa Azuma, Yoshiko Tsubokura, Yukie Saito, Ryo Hotta, Masaaki Yoshimura, Hideaki Ishii, Kazuyoshi Ito, Tomoki Nomura, Shosaku Leuk Res Rep Article BACKGROUND: Although eltrombopag has recently been approved for treating AA, the effects of its clinical use remain unknown. METHODS: We retrospectively analyzed 11 patients with AA, who had been treated with eltrombopag from August 2017 to May 2018. RESULTS: Overall response rate was 55%. There was tri-lineage recovery in four patients and platelet recovery in two. The reactive time was within 8 weeks after treatment initiation. Stage at the initial assessment, the neutrophil-to-lymphocyte ratio and platelet counts were significantly different between the responders and non-responders. CONCLUSION: Eltrombopag is a promising agent for treating patients with any degree of AA. Elsevier 2019-03-05 /pmc/articles/PMC6416522/ /pubmed/30911464 http://dx.doi.org/10.1016/j.lrr.2019.03.002 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Konishi, Akiko
Nakaya, Aya
Fujita, Shinya
Satake, Atsushi
Nakanishi, Takahisa
Azuma, Yoshiko
Tsubokura, Yukie
Saito, Ryo
Hotta, Masaaki
Yoshimura, Hideaki
Ishii, Kazuyoshi
Ito, Tomoki
Nomura, Shosaku
Evaluation of eltrombopag in patients with aplastic anemia in real-world experience
title Evaluation of eltrombopag in patients with aplastic anemia in real-world experience
title_full Evaluation of eltrombopag in patients with aplastic anemia in real-world experience
title_fullStr Evaluation of eltrombopag in patients with aplastic anemia in real-world experience
title_full_unstemmed Evaluation of eltrombopag in patients with aplastic anemia in real-world experience
title_short Evaluation of eltrombopag in patients with aplastic anemia in real-world experience
title_sort evaluation of eltrombopag in patients with aplastic anemia in real-world experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416522/
https://www.ncbi.nlm.nih.gov/pubmed/30911464
http://dx.doi.org/10.1016/j.lrr.2019.03.002
work_keys_str_mv AT konishiakiko evaluationofeltrombopaginpatientswithaplasticanemiainrealworldexperience
AT nakayaaya evaluationofeltrombopaginpatientswithaplasticanemiainrealworldexperience
AT fujitashinya evaluationofeltrombopaginpatientswithaplasticanemiainrealworldexperience
AT satakeatsushi evaluationofeltrombopaginpatientswithaplasticanemiainrealworldexperience
AT nakanishitakahisa evaluationofeltrombopaginpatientswithaplasticanemiainrealworldexperience
AT azumayoshiko evaluationofeltrombopaginpatientswithaplasticanemiainrealworldexperience
AT tsubokurayukie evaluationofeltrombopaginpatientswithaplasticanemiainrealworldexperience
AT saitoryo evaluationofeltrombopaginpatientswithaplasticanemiainrealworldexperience
AT hottamasaaki evaluationofeltrombopaginpatientswithaplasticanemiainrealworldexperience
AT yoshimurahideaki evaluationofeltrombopaginpatientswithaplasticanemiainrealworldexperience
AT ishiikazuyoshi evaluationofeltrombopaginpatientswithaplasticanemiainrealworldexperience
AT itotomoki evaluationofeltrombopaginpatientswithaplasticanemiainrealworldexperience
AT nomurashosaku evaluationofeltrombopaginpatientswithaplasticanemiainrealworldexperience

Ejemplares similares